ABUS
EquityArbutus Biopharma Corporation
Health Care · Biotechnology
$4.72
+4.72 (+0.00%)
Open
N/A
Day Range
$4.30 - $4.81
52W Range
$2.71 - $5.10
Volume
10M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Sector Update: Health Care Stocks Rise in Afternoon Trading
Sector Update: Health Care
Moderna to pay up to $2.25B to settle COVID vaccine patent matter
Moderna Stock Shoots Up on $2.3 Billion Patent Settlement
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| A | Agilent Technologies, Inc. | $120.24 | N/A | 0.83% | +0.00% |
| CRSP | CRISPR Therapeutics AG | $59.95 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $234.67 | N/A | 2.83% | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.65 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.26 | N/A | - | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.66 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $23.06 | N/A | - | +0.00% |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
www.arbutusbio.com →🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for ABUS
🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for ABUS.